Myasthenia Gravis Drug Received European Recommendation
Adults with a specific form of myasthenia gravis may soon have a new add-on therapy option to manage their symptoms.
Updated on Sept. 21, 2026 in Alzheimer’s
Live Poll
Do you believe new specialty drugs for rare autoimmune conditions generally provide sufficient benefits to patients?
The European Medicines Agency committee has recommended Klygefa for approval to treat adults with anti-acetylcholine receptor antibody-positive generalised myasthenia gravis. This medication is designed to function as an add-on therapy to existing standard treatment regimens.
Why it matters
This recommendation offers a potential new treatment pathway for patients whose symptoms remain difficult to control with standard therapies alone. It addresses the need for targeted immune-system intervention to improve daily function and disease severity in this population.
In the 260-patient PREVAIL trial, Klygefa achieved a statistically significant treatment difference of -1.6 in MG-ADL scores compared to placebo at week 26 (p<0.0001). This phase III evidence supports the drug as an add-on therapy for AChR-positive generalised myasthenia gravis.
The players
European Medicines Agency
The European Union agency responsible for the scientific evaluation and supervision of medicinal products.
Committee for Medicinal Products for Human Use
The expert committee within the EMA that issues opinions on the authorization of medicines for human use.
The details
Klygefa is a dual-binding nanobody C5 inhibitor that functions by binding to the C5 protein within the terminal complement cascade. By inhibiting this protein, the medication prevents the immune system from launching an over-response that attacks neuromuscular junctions. Patients in the trial received a weight-based loading dose on Day 1, followed by regular weekly maintenance doses to sustain this inhibition.
Timeline
Day 1: Patients received a single loading dose of the medication.
Day 8: Regular weekly maintenance dosing began for participants.
Week 1: Researchers observed clinically meaningful improvements in symptoms.
Week 26: The study measured the primary endpoint of total MG-ADL score.
2025 Annual Meeting: PREVAIL trial results were officially presented.
Health Landscape
Klygefa follows the development of other therapies targeting the terminal complement cascade inhibition pathway to manage autoimmune damage. It marks a potential evolution in the standard of care by introducing a dual-binding nanobody approach for patients with this specific antibody profile.
If you are living with AChR-positive generalised myasthenia gravis, this development highlights a new potential therapeutic option currently moving through global regulatory pipelines. It is worth discussing with your neurologist whether targeted complement inhibitors could be a suitable addition to your current care plan.
The takeaway
Targeted therapies continue to provide new options for managing chronic autoimmune symptoms that do not fully respond to standard treatments. Patients are encouraged to track their daily functional scores and consult with a neuromuscular specialist to see if emerging complement-targeting drugs align with their care needs.
Further reading
Learn more about the latest developments in managing neurological conditions at our Alzheimer’s section.
Live Poll
Do you believe new specialty drugs for rare autoimmune conditions generally provide sufficient benefits to patients?
